FDA Green Lights AstraZeneca, Merck's Lynparza for Metastatic Breast Cancer Post author:Sam Post published:January 11, 2018 Post category:BioPharma Lynparza is the first and only PARP inhibitor approved for use beyond ovarian cancer. Source: BioSpace You Might Also Like <b>Novigenix</b> Signs Distribution Agreement With <b>Dr Risch Medical Laboratory</b> To Access Swiss German Market For Colox, Its Blood Based Colorectal Cancer Test March 14, 2017 Bay Area Avinger Cuts Workforce by 33% April 10, 2017 Radius Health's Longtime CEO Out, Former Novo Nordisk A/S Exec Named New Leader July 16, 2017
<b>Novigenix</b> Signs Distribution Agreement With <b>Dr Risch Medical Laboratory</b> To Access Swiss German Market For Colox, Its Blood Based Colorectal Cancer Test March 14, 2017
